Company news

Firebrick Pharma Limited news

Latest news releases, newest first. Pick a year for every news release, call and deck from that year.

View company

Agreement Signed to Market Nasodine to HCPs in Singapore

October 30, 2024

September 2024 Quarterly Activity Report & Appendix 4C

October 22, 2024

Completion of Share Purchase Plan

October 9, 2024

Firebrick receives $0.9 million R&D Tax Incentive

September 22, 2024

Share Purchase Plan

September 11, 2024

Appendix 4E and Annual Report 30 June 2024

August 30, 2024

New agreement allows Nasodine launch in Philippines

August 14, 2024

June 2024 Quarterly Activity Report & Appendix 4C

July 29, 2024

Firebrick Launches Nasodine in Singapore

June 12, 2024

Firebrick Raises $800,000 via Placement

May 16, 2024

March 2024 Quarterly Activity Report & Appendix 4C

April 22, 2024

Nasodine Nasal Spray Launch in the USA

April 16, 2024

Appendix 4D & Half-Year Financial Report to 31 December 2023

February 28, 2024

December 2023 Quarterly Activity Report & Appendix 4C

January 23, 2024

Firebrick Investor Update

November 14, 2023

Firebrick Receives $1.81m R&D Tax Incentive

October 30, 2023

September 2023 Quarterly Activity Report & Appendix 4C

October 26, 2023

Update on Nasodine Trial and Forward Plans

October 2, 2023

Phase 3 Common Cold Trial Results

September 13, 2023

Appendix 4E & Annual Report FY23

August 29, 2023

Response to ASX Price and Volume Query

August 28, 2023

Firebrick Phase 3 Trial Closes with 500 Subjects

August 8, 2023

Firebrick Covid-19 Trial Achieves Primary Endpoint

August 6, 2023

June 2023 Quarterly Activity Report & Appendix 4C

July 26, 2023

Nasodine Phase 3 Clinical Trial Surpasses 80% Recruitment

May 30, 2023

Firebrick Raises $1 million via Placement

April 30, 2023

March 2023 Quarterly Activity Report & Appendix 4C

April 19, 2023

Nasodine COVID-19 Trial Concludes Recruitment

April 3, 2023

Firebrick Pharmas Phase 3 Trial of Nasodine Resumes

March 20, 2023

FRE files EU Paediatric Investigation Plan for Nasodine

February 20, 2023

Appendix 4D & Half Yearly Report and Accounts

February 17, 2023

December 2022 Quarterly Activity Report & Appendix 4C

January 18, 2023

Nasodine Composition Patent Accepted in Australia

November 13, 2022

Firebrick Receives $1.08m R&D Tax Incentive

November 8, 2022

September 2022 Quarterly Activity Report & Appendix 4C

October 31, 2022

Appendix 4E & Annual Report

August 23, 2022

June 2022 Quarterly Activity Report & Appendix 4C

July 28, 2022

Outcome of s60 appeal for Nasodine and next steps

July 7, 2022

Firebrick starts Phase 3 common cold trial of Nasodine

May 3, 2022

March 2022 Quarterly Activity Report & Appendix 4C

April 26, 2022

Firebrick starts COVID-19 trial of Nasodine

April 26, 2022

31 December Interim Financial Report & Appendix 4D

February 11, 2022

← Newer news releases

Decks

The 5 newest of 9 decks. Every deck is listed under its year.